Servier Pharmaceuticals, shared on LinkedIn:
“Two years ago, Servier helped redefine the treatment landscape for Grade 2 IDH-mutant glioma by bringing the first and only FDA-approved medicine to patients living with this disease in more than two decades.
Our focus remains on driving continued progress for the patients and families impacted by glioma and other IDH-mutated cancers.
